Precision Oncology and Genomically Guided Radiation Therapy, A Report From the ASTRO/AAPM/NCI Precision Medicine Conference

[1]  Ash A. Alizadeh,et al.  Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. , 2017, Cancer discovery.

[2]  Jacob G. Scott,et al.  A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. , 2017, The Lancet. Oncology.

[3]  Petra Seibold,et al.  Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  Christian Nicolaj Andreassen,et al.  Radiogenomics - current status, challenges and future directions. , 2016, Cancer letters.

[5]  Adam P Dicker,et al.  Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. , 2016, The Lancet. Oncology.

[6]  Anil Vachani,et al.  Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA , 2016, Clinical Cancer Research.

[7]  John Humm,et al.  Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma. , 2016, International journal of radiation oncology, biology, physics.

[8]  S. Eschrich,et al.  Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. , 2016, International journal of radiation oncology, biology, physics.

[9]  Richard Stock,et al.  Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer , 2016, EBioMedicine.

[10]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[11]  C. N. Coleman,et al.  Radiotherapy: Changing the Game in Immunotherapy. , 2016, Trends in cancer.

[12]  Jens Overgaard,et al.  Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials , 2016, Acta oncologica.

[13]  D. Aust,et al.  Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG , 2016, Clinical Cancer Research.

[14]  C. Taniguchi,et al.  XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients , 2016 .

[15]  Steven Eschrich,et al.  The radiosensitivity index predicts for overall survival in glioblastoma , 2015, Oncotarget.

[16]  Nawaid Usmani,et al.  The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models: A Step Toward Prevention. , 2015, Seminars in radiation oncology.

[17]  Ash A. Alizadeh,et al.  Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. , 2015, Seminars in radiation oncology.

[18]  Janet T. Lee,et al.  Systematic Review of Candidate Single-nucleotide Polymorphisms as Biomarkers for Responsiveness to Neoadjuvant Chemoradiation for Rectal Cancer. , 2015, Anticancer research.

[19]  Felix Y. Feng,et al.  Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer , 2015, Clinical Cancer Research.

[20]  V. Budach,et al.  HPV in , 2014 .

[21]  P. Harari,et al.  Interaction of radiation therapy with molecular targeted agents. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[23]  E. Miles,et al.  NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[24]  P. Lambin,et al.  The REQUITE project: validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[25]  David J Brenner,et al.  The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? , 2014, International journal of radiation oncology, biology, physics.

[26]  Jeff Shrager,et al.  Rapid learning for precision oncology , 2014, Nature Reviews Clinical Oncology.

[27]  Sarah L Kerns,et al.  Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy. , 2014, Cancer discovery.

[28]  R. Steenbakkers,et al.  Head and Neck Tumor Hypoxia Imaging by 18F-Fluoroazomycin-arabinoside (18F-FAZA)-PET: A Review , 2014, Clinical nuclear medicine.

[29]  Joseph O Deasy,et al.  STROGAR – STrengthening the Reporting Of Genetic Association studies in Radiogenomics , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  Catherine C. Park,et al.  Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. , 2014, International journal of radiation oncology, biology, physics.

[31]  Lisa McShane,et al.  National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[32]  Anirban P. Mitra,et al.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. , 2013, The Journal of urology.

[33]  R. Bristow,et al.  Tumor hypoxia as a driving force in genetic instability , 2013, Genome Integrity.

[34]  J. Mesirov,et al.  Integrative radiogenomic profiling of squamous cell lung cancer. , 2013, Cancer research.

[35]  William L. Welbourn,et al.  Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. , 2013, International journal of radiation oncology, biology, physics.

[36]  P. Harari,et al.  Enhanced radiation sensitivity in HPV-positive head and neck cancer. , 2013, Cancer research.

[37]  Crispin J. Miller,et al.  A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer , 2013, Clinical Cancer Research.

[38]  M. Steinberg,et al.  National Institutes of Health funding in radiation oncology: a snapshot. , 2013, International journal of radiation oncology, biology, physics.

[39]  Seon-Young Kim,et al.  Novel single-nucleotide polymorphism markers predictive of pathologic response to preoperative chemoradiation therapy in rectal cancer patients. , 2013, International journal of radiation oncology, biology, physics.

[40]  George W. Sledge,et al.  A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast , 2013, Journal of the National Cancer Institute.

[41]  T. Grob,et al.  HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[42]  J. Petersen,et al.  Imaging hypoxia to improve radiotherapy outcome , 2012, Nature Reviews Clinical Oncology.

[43]  Michael Baumann,et al.  Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[44]  J. Stockman.  Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer , 2012 .

[45]  M. Sydes,et al.  Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. , 2012, The Lancet. Oncology.

[46]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[47]  I. Yeo,et al.  Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy , 2011, Journal of applied clinical medical physics.

[48]  E. Montgomery,et al.  Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group , 2011, BMC Cancer.

[49]  Richard Stock,et al.  Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. , 2010, International journal of radiation oncology, biology, physics.

[50]  Krishna R. Kalari,et al.  Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. , 2010, Genome research.

[51]  Crispin J. Miller,et al.  Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene , 2010, British Journal of Cancer.

[52]  Barry S Rosenstein,et al.  Establishment of a radiogenomics consortium. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[53]  O. Jäkel.  Medical physics aspects of particle therapy. , 2009, Radiation protection dosimetry.

[54]  David Boulware,et al.  A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. , 2009, International journal of radiation oncology, biology, physics.

[55]  J. Alsner,et al.  Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[56]  H. Willers,et al.  Introduction to clinical radiation biology. , 2006, Hematology/oncology clinics of North America.

[57]  D. Brizel,et al.  Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[58]  Steven Eschrich,et al.  Prediction of radiation sensitivity using a gene expression classifier. , 2005, Cancer research.

[59]  J. Hendry,et al.  Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[60]  J. Overgaard,et al.  A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[61]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.